phrykt

Inhibikase Therapeutics, Inc. (IKT): who owns it and who trades it

As of Nov 16, 2026, IKT insiders reported 1 purchase worth $3M in the last 12 months. The largest buyer was Frank M. Sands (10% owner), with $3M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Inhibikase Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IKT

106 funds and institutions reported IKT shares worth $253M at the end of Q2 2026, about 94% of the company. The largest holder is Sands Capital Alternatives, LLC with 9.9%.

Funds and institutions (13F) 94%Everyone else 6%

10 largest owners, by share of the company

Sands Capital Alternatives, LLC9.9%
Soleus Capital Management, L.P.8.2%
Trails Edge Capital Partners, LP6.9%
Fairmount Funds Management LLC6.5%
BlackRock, Inc.5.9%
Kalehua Capital Management LLC5.8%
ADAR1 Capital Management, LLC5.6%
Blackstone Inc.4.5%
Siren, L.L.C.4.4%
Nantahala Capital Management, LLC4.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Sands Capital Alternatives, LLC13.02M9.86%$26.4MNo change
Soleus Capital Management, L.P.10.88M8.24%$22.1MNo change
Trails Edge Capital Partners, LP9.05M6.86%$18.4M+12%
Fairmount Funds Management LLC8.62M6.53%$17.5MNo change
BlackRock, Inc.7.77M5.88%$15.8M+23%
Kalehua Capital Management LLC7.64M5.79%$15.5M+18%
ADAR1 Capital Management, LLC7.39M5.59%$15M+12%
Blackstone Inc.5.94M4.50%$12.1MNo change
Siren, L.L.C.5.85M4.43%$11.9MNo change
Nantahala Capital Management, LLC5.40M4.09%$11M+100%
Commodore Capital LP5.40M4.09%$11MNo change
Vanguard Capital Management LLC4.94M3.74%$10M+11%
Millennium Management LLC4.03M3.05%$8.2M+38%
Saturn V Capital Management LP3.87M2.93%$7.9M+0%
Spruce Street Capital LP3.58M2.71%$7.3MNo change
Squadron Capital Management LLC3.00M2.27%$6.1M-14%
Geode Capital Management, LLC2.61M1.97%$5.3M+20%
State Street Corp1.91M1.45%$3.9M+13%
SummitTX Capital, L.P.1.78M1.35%$3.6M+17%
Integral Health Asset Management, LLC1.35M1.02%$2.7MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IKT insiders reported $3M of open-market purchases and $0 of sales.

Purchases, 12 months
$3M
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 21, 2025
Filed Nov 24, 2025

Purchases and sales by month

$1$1DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 21, 2025Frank M. Sands +210% ownerPurchase2.07M$1.45$3MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Frank M. Sands10% owner$3M–Nov 21, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IKT short interest

High short interest. 13.9% of IKT shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 19.43M IKT shares were sold short, 13.9% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 679,671 shares, buying them all back would take about 28.6 trading days (days to cover).

Shares short, % of all shares

13.9%May 15Oct 3014.9%

Days to cover

28.6May 15Oct 3052.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202619.43M13.92%-1%679,67128.6
Oct 15, 202619.63M14.07%+1%632,00731.1
Sep 30, 202619.43M13.92%+5%719,28327.0
Sep 15, 202618.52M13.27%-5%389,96747.5
Aug 31, 202619.49M13.97%-1%411,22847.4
Aug 14, 202619.67M14.09%+3%553,48935.5
Jul 31, 202619.14M14.49%+5%890,63721.5
Jul 15, 202618.26M13.83%-6%1.08M16.9
Jun 30, 202619.42M14.71%+3%1.12M17.4
Jun 15, 202618.89M14.31%+2%549,86034.4
May 29, 202618.51M14.02%+5%753,43024.6
May 15, 202617.69M13.40%-2%667,10326.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Inhibikase Therapeutics company events

Inhibikase Therapeutics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 20, 2026LeadershipDennis Berman resigned from the board of directors of Inhibikase Therapeutics, Inc. and his position as Chair of the Compensation Committee of the Board and a member of the Audit Committee of the Board, effective as of October 19, 2026. Filing
  3. Sep 8, 2026AnnouncementShared information with investors. Filing
  4. Aug 26, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  5. Aug 11, 2026ResultsReleased financial results. Filing
  6. Jul 29, 2026SharesSold new shares outside a public offering. Filing
  7. Jul 23, 2026AnnouncementShared information with investors. Filing
  8. Jul 14, 2026AnnouncementInhibikase Therapeutics, Inc. issued a press release relating to sales made by the Company under its at-the-market facility. Filing
  9. Jun 29, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  10. May 12, 2026ResultsReleased financial results. Filing
  11. Apr 7, 2026AnnouncementShared information with investors. Filing
  12. Mar 26, 2026ResultsReleased financial results. Filing
  13. Dec 19, 2025AnnouncementInhibikase Therapeutics, Inc. filed with the Securities and Exchange Commission a prospectus supplement, dated December 19, 2025, with respect to the Company’s existing “at the market offering” program. Filing
  14. Nov 21, 2025AgreementInhibikase Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto, relating to an underwritten public offering of (i) 46,091,739 shares of the… Filing
  15. Nov 20, 2025AnnouncementInhibikase Therapeutics, Inc. announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hypertension. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Inhibikase Therapeutics financials

Famous investors that hold IKT

2 of the 50 well-known investors we track reported holding IKT in their latest 13F filing. The largest position is Israel Englander's, worth $8.2M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.97M$8.2M0.0%-2%
Ken Griffin · Citadel AdvisorsQ3 202669,495$143K0.0%-7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Inhibikase Therapeutics, Inc. (IKT) stock

Who owns the most IKT stock?

The largest reported owner of Inhibikase Therapeutics, Inc. (IKT) is Sands Capital Alternatives, LLC, with 9.9% of the company. In total, 106 funds and institutions reported holding IKT at the end of Q2 2026, together about 94% of the shares. See the largest owners.

Are IKT insiders buying or selling?

In the last 12 months, IKT insiders reported 1 open-market purchase worth $3M and no sales. The latest trade was on Nov 21, 2025. See every trade.

What is the short interest in IKT?

As of Oct 30, 2026, 19.43M IKT shares were sold short, 13.9% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 679,671 shares, buying them all back would take about 28.6 trading days (days to cover). See the history.

Which famous investors hold IKT?

2 of the 50 well-known investors we track reported IKT in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $8.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.